The U.S. expects to distribute 6.4 million doses of Pfizer and BioNTech's shot by mid-December, should the vaccine pass the FDA's bar, Department of Health and Human Services secretary Alex Azar said. Meanwhile, the World Health Organization's vaccine distribution effort, COVAX, has locked down hundreds of millions of AstraZeneca doses.
Shanghai Fosun and BioNTech plan to launch a phase 2 trial of the German mRNA specialist's vaccine hopeful, BNT162b2, in China. Plus, Sinopharm has reportedly filed for official approval to market one or more of its experimental vaccines.
States will have final say over how to distribute the first slate of vaccines, Alex Azar said. Plus, the European Union wants to expedite the process for waiving intellectual property rights to make generic drugs during the pandemic.
The worldwide case count passed 59.9 million Wednesday morning, with more than 1.41 million reported deaths, according to Johns Hopkins University's COVID-19 dashboard.